Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation

被引:0
作者
Carter, RJ
Lione, LA
Humby, T
Mangiarini, L
Mahal, A
Bates, GP
Dunnett, SB
Morton, AJ
机构
[1] Univ Cambridge, Dept Pharmacol, Cambridge CB2 1QJ, England
[2] Univ Cambridge, Ctr Brain Repair, Cambridge CB2 1QJ, England
[3] Univ Cambridge, Parke Davis Neurosci Res, Cambridge CB2 1QJ, England
[4] Univ Cambridge, Dept Expt Psychol, Cambridge CB2 1QJ, England
[5] Guys Hosp, Div Med & Mol Genet, London SE1 9RT, England
基金
英国惠康基金;
关键词
transgenic mice; Huntington's disease; CAG repeat; motor behavior; prepulse inhibition; sensorimotor gating; polyglutamine repeat diseases;
D O I
暂无
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Transgenic mice expressing exon 1 of the human Huntington's disease (HD) gene carrying a 141-157 CAG repeat (line R6/2) develop a progressive neurological phenotype with motor symptoms resembling those seen in HD. We have characterized the motor deficits in R6/2 mice using a battery of behavioral tests selected to measure motor aspects of swimming, fore- and hindlimb coordination, balance, and sensorimotor gating [swimming tank, rotarod, raised beam, fore- and hindpaw footprinting, and acoustic startle/prepulse inhibition (PPI)I. Behavioral testing was performed on female hemizygotic R6/2 transgenic mice (n = 9) and female wild-type littermates (n = 22) between 5 and 14 weeks of age. Transgenic mice did not show an overt behavioral phenotype until around 8 weeks of age. However, as early as 5-6 weeks of age they had significant difficulty swimming, traversing the narrowest square (5 mm) raised beam, and maintaining balance on the rotarod at rotation speeds of 33-44 rpm. Furthermore, they showed significant impairment in prepulse inhibition tan impairment also seen in patients with HD). Between 8 and 15 weeks, R6/2 transgenic mice showed a progressive deterioration in performance on all of the motor tests. Thus R6/2 mice show measurable deficits in motor behavior that begin subtly and increase progressively until death. Our data support the use of R6/2 mice as a model of HD and indicate that they may be useful for evaluating therapeutic strategies for HD, particularly those aimed at reducing the severity of motor symptoms or slowing the course of the disease.
引用
收藏
页码:3248 / 3257
页数:10
相关论文
共 50 条
  • [31] Increased Formation of Reactive Oxygen Species, but No Changes in Glutathione Peroxidase Activity, in Striata of Mice Transgenic for the Huntington's Disease Mutation
    Francisca Pérez-Severiano
    Abel Santamaría
    José Pedraza-Chaverri
    Omar N. Medina-Campos
    Camilo Ríos
    José Segovia
    Neurochemical Research, 2004, 29 : 729 - 733
  • [32] Mice transgenic for the Huntington's disease mutation are resistant to chronic 3-nitropropionic acid-induced striatal toxicity
    Hickey, MA
    Morton, AJ
    JOURNAL OF NEUROCHEMISTRY, 2000, 75 (05) : 2163 - 2171
  • [33] Motor function and dopamine release measurements in transgenic Huntington's disease model rats
    Ortiz, Andrea N.
    Osterhaus, Gregory L.
    Lauderdale, Kelli
    Mahoney, Luke
    Fowler, Stephen C.
    von Hoersten, Stephan
    Riess, Olaf
    Johnson, Michael A.
    BRAIN RESEARCH, 2012, 1450 : 148 - 156
  • [34] Adenoviral Astrocyte-Specific Expression of BDNF in the Striata of Mice Transgenic for Huntington's Disease Delays the Onset of the Motor Phenotype
    Arregui, Leticia
    Benitez, Jorge A.
    Razgado, Luis F.
    Vergara, Paula
    Segovia, Jose
    CELLULAR AND MOLECULAR NEUROBIOLOGY, 2011, 31 (08) : 1229 - 1243
  • [35] Increased formation of reactive oxygen species, but no changes in glutathione peroxidase activity, in striata of mice transgenic for the Huntington's disease mutation
    Pérez-Severiano, F
    Santamariá, A
    Pedraza-Chaverri, J
    Medina-Campos, ON
    Ríos, C
    Segovia, J
    NEUROCHEMICAL RESEARCH, 2004, 29 (04) : 729 - 733
  • [36] Striatal neurochemical changes in transgenic models of Huntington's disease
    Ariano, MA
    Aronin, N
    Difiglia, M
    Tagle, DA
    Sibley, DR
    Leavitt, BR
    Hayden, MR
    Levine, MS
    JOURNAL OF NEUROSCIENCE RESEARCH, 2002, 68 (06) : 716 - 729
  • [37] Adenoviral Astrocyte-Specific Expression of BDNF in the Striata of Mice Transgenic for Huntington’s Disease Delays the Onset of the Motor Phenotype
    Leticia Arregui
    Jorge A. Benítez
    Luis F. Razgado
    Paula Vergara
    Jose Segovia
    Cellular and Molecular Neurobiology, 2011, 31 : 1229 - 1243
  • [38] Metformin therapy in a transgenic mouse model of Huntington's disease
    Ma, Thong C.
    Buescher, Jessica L.
    Oatis, Benjamin
    Funk, Jason A.
    Nash, Andrew J.
    Carrier, Raeann L.
    Hoyt, Kari R.
    NEUROSCIENCE LETTERS, 2007, 411 (02) : 98 - 103
  • [39] Light and electron microscopic characterization of the evolution of cellular pathology in YAC128 Huntington's disease transgenic mice
    Bayram-Weston, Zubeyde
    Jones, Lesley
    Dunnett, Stephen B.
    Brooks, Simon P.
    BRAIN RESEARCH BULLETIN, 2012, 88 (2-3) : 137 - 147
  • [40] A Transgenic Minipig Model of Huntington's Disease
    Baxa, Monika
    Hruska-Plochan, Marian
    Juhas, Stefan
    Vodicka, Petr
    Pavlok, Antonin
    Juhasova, Jana
    Miyanohara, Atsushi
    Nejime, Tetsuya
    Klima, Jiri
    Macakova, Monika
    Marsala, Silvia
    Weiss, Andreas
    Kubickova, Svatava
    Musilova, Petra
    Vrtel, Radek
    Sontag, Emily M.
    Thompson, Leslie M.
    Schier, Jan
    Hansikova, Hana
    Howland, David S.
    Cattaneo, Elena
    DiFiglia, Marian
    Marsala, Martin
    Motlik, Jan
    JOURNAL OF HUNTINGTONS DISEASE, 2013, 2 (01) : 47 - 68